Lobular carcinoma in situ at percutaneous breast biopsy: Surgical biopsy findings

American Journal of Roentgenology

Volumn 173, Issue 2, 1999, Pages 291-299

  Liberman, Laura ^a   Sama, Michelle ^a   Susnik, Barbara ^a   Rosen, Paul Peter ^a,b   LaTrenta, Linda R ^a   Morris, Elizabeth A ^a   Abramson, Andrea F ^a   Dershaw, D David ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b White Plains Hospital Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BREAST BIOPSY; BREAST CARCINOMA; BREAST HYPERPLASIA; BREAST LESION; CARCINOMA IN SITU; ECHOGRAPHY; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PERCUTANEOUS BIOPSY; PRIORITY JOURNAL;

EID: 0032769315     PISSN: 0361803X     EISSN: None     Source Type: Journal    
DOI: 10.2214/ajr.173.2.10430122     Document Type: Article

References (36)

1. Foote FW Jr, Stewart FW. Lobular carcinoma in situ: a rare form of mammary cancer. Am J Pathol 1941;17:491-496
2. Rosen PP. Lobular carcinoma in situ and atypical lobular hyperplasia. In: Rosen's breast pathology. Philadelphia: Lippincott-Raven, 1997:507-544
3. Anderson J. Lobular carcinoma in situ: a long-term follow-up in 52 cases. Acta Pathol Microbiol Scand [A] 1974;82:519-533
4. Rosen PP, Lieberman PH, Braun DW Jr, Kosloff C, Adair F. Lobular carcinoma in situ of the breast: detailed analysis of 99 patients with average follow-up of 24 years. Am J Surg Pathol 1978;2:225-251
5. Haagensen CD. Lobular neoplasia (lobular carcinoma in situ). In: Diseases of the breast, 3rd ed. Philadelphia: Saunders, 1986:192-241
6. Haagensen CD, Lane N, Lattes R, Bodian C. Lobular neoplasia (so-called lobular carcinoma in situ) of the breast. Cancer 1978;42:737-769
7. Page DL, Kidd TE Jr, Dupont WD, Simpson JF, Rogers LW. Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease. Hum Pathol 1991;22:1232-1239
8. Bodian CA, Perzin KH, Lattes R, Huffman P, Abernathy TG. Prognostic significance of benign proliferative disease. Cancer 1993;71:3896-3907
9. Bodian CA, Perzin KH, Lattes R. Lobular neoplasia: long term risk of breast cancer and relation to other factors. Cancer 1996;78:1024-1034
10. Page DL, Van der Zwaag R, Rogers LW, Williams LT, Walker WE, Hartmann WH. Relation between component parts of fibrocystic disease complex and breast cancer. J Natl Cancer Inst 1978;61:1055-1063
11. Page DL, Dupont WD, Rogers LW, Rados MS. Atypical hyperplastic lesions of the female breast a long-term follow-up study. Cancer 1985;55:2698-2708
12. Osborne MP, Hoda SA. Current management of lobular carcinoma in situ of the breast. Oncology 1994;8:45-49
13. Carson W, Sanchez-Forgach E, Stomper P, Penetrante R, Tsangaris TN, Edge SB. Lobular carcinoma in situ: observation without surgery as an appropriate therapy. Ann Surg Oncol 1994;1:141-146
14. Gump FE, Kinne D, Schwartz GF. Current treatment for lobular carcinoma in situ. Ann Surg Oncol 1998;5:33-36
15. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 1998;351:1451-1467
16. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90: 1371-1388
17. Cummings SR, Norton L, Eckert S, et al. Raloxifene reduces the risk of breast cancer and may decrease the risk of endometrial cancer in post-menopausal women: two-year findings from the multiple outcomes of raloxifene evaluation (MORE) trial (abstr). In: Perry MC, ed. Program/proceedings of the American Society of Clinical Oncology, vol. 17. Philadelphia: Saunders, 1998:2a
18. Jordan VC, Glusman JE, Eckert S, et al. Incident primary breast cancers are reduced by raloxifene: integrated data from multicenter, double-blind, randomized trials in 12,000 postmenopausal women (abstr). In: Perry MC, ed. Program/proceedings of the American Society of Clinical Oncology, vol. 17. Philadelphia: Saunders, 1998:122a
19. Bassett L, Winchester DP, Caplan RB, et al. Stereotactic core-needle biopsy of the breast: a report of the Joint Task Force of the American College of Radiology, American College of Surgeons, and College of American Pathologisis. CA Cancer J Clin 1997;47:171-190
20. Jackman RJ, Nowels KW, Shepard MJ, Finkelstein SI, Marzoni FA. Stereotaxic large-core needle biopsy of 450 nonpalpable breast lesions with surgical correlation in lesions with cancer or atypical hyperplasia. Radiology 1994;193:91-95
21. Liberman L, Cohen MA, Dershaw DD, Abramson AF, Hann LE, Rosen PP. Atypical ductal hyperplasia diagnosed at stereotaxic core biopsy of breast lesions: an indication for surgical biopsy. AJR 1995;164:1111-1113
22. Meyer JE, Smith DN, Lester SC, et al. Large-needle core biopsy: nonmalignant breast abnormalities evaluated with surgical excision or repeat core biopsy. Radiology 1998;206:717-720
23. Burbank F. Stereotactic breast biopsy of atypical ductal hyperplasia and ductal carcinoma in situ lesions: improved accuracy with a directional, vacuum-assisted biopsy instrument. Radiology 1997;202:843-847
24. Jackman RJ, Burbank FH, Parker SH, et al. Atypical ductal hyperplasia diagnosed by 11-gauge, directional, vacuum-assisted breast biopsy: how often is carcinoma found at surgery? (abstr). Radiology 1997;205(P):325
25. Liberman L, Smolkin JH, Dershaw DD, Morris EA, Abramson AF, Rosen PP. Calcification retrieval at stereotactic, 11-gauge, directional, vacuum-assisted breast biopsy. Radiology 1998;208:251-260
26. Liberman L, Dershaw DD, Glassman JR, et al. Analysis of cancers not diagnosed at stereotactic core breast biopsy. Radiology 1997;203:151-157
27. Jackman RJ, Nowels KW, Rodriguez-Soto J, Marzoni FA, Finkelstein SI, Shepard MJ. Stereotactic, automated, large-core needle biopsy of nonpalpable breast lesions: false-negative and histologic underestimation rates after long-term follow-up. Radiology 1999;210:799-805
28. Lee CH, Egglin TIK, Philpotts LE, et al. Cost-effectiveness of stereotactic core needle biopsy: analysis by means of mammographic findings. Radiology 1997;202:849-854
29. Lentner C. 'Exact' confidence limits for p. In: Lentner C, ed. Geigy scientific tables, vol 2. Introduction to statistics, statistical tables, mathematical formulae. Basle, Switzerland: Ciba-Geigy, 1982;89-102
30. Snyder RE. Mammography and lobular carcinoma in-situ. Surg Gynecol Obstet 1966;122:255-260
31. Hutter RVP, Snyder RE, Lucas CJ, Foote FW, Farrow JH. Clinical and pathologic correlation with mammographic findings in lobular carcinoma in-situ. Cancer 1969;23:826-839
32. Pope TL Jr, Fechner RE, Wilhelm MC, Wanebo HJ, de Paredes ES. Lobular carcinoma in situ of the breast: mammographic features. Radiology 1988;168:63-66
33. Beute BJ, Kalisher L, Hutter RVP. Lobular carcinoma in situ of the breast: clinical, pathologic, and mammographic features. AJR 1991;157:257-265
34. Rosen PP. Radial sclerosing lesions. In: Rosen's breast pathology. Philadelphia: Lippincott-Raven, 1997:76-81
35. Fuhrman GM, Cederbom GJ, Bolton JS, et al. Image-guided core-needle breast biopsy is an accurate technique to evaluate patients with nonpalpable imaging abnormalities. Ann Surg 1998;6:932-939
36. Berlin L. Tracking for breast cancer (commentary). AJR 1998;170:93-95